Home › Multiple Sclerosis › Maryland
Multiple Sclerosis clinical trials in Maryland
17 studies for Multiple Sclerosis are looking for participants at sites in Maryland.
Cities in Maryland
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Baltimore
- TG Therapeutics Investigational Trial Site, Glen Burnie
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06433752Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
1 Month – 99 Years · All sexes · Updated Sep 22, 2026 · NCT00794352Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 120 · All sexes · Updated Sep 16, 2026 · NCT00001248Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Sep 16, 2026 · NCT02784210Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Baltimore Veterans Affairs Medical Center- Site Number : 8400163, Baltimore
RecruitingPhase 3
Ages 18 to 60 · All sexes · Updated Sep 15, 2026 · NCT07325292RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Sunstone Therapies, PC, Rockville
- Sheppard Pratt, Towson
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 15, 2026 · NCT07002034Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 120 · All sexes · Updated Aug 31, 2026 · NCT01730131Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Aug 27, 2026 · NCT03109288A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Mid Atlantic Epilepsy and Sleep Ctr, Bethesda
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 29, 2026 · NCT07225504Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
- Johns Hopkins University, Baltimore
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Jul 17, 2026 · NCT07497399Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
- Johns Hopkins University, Baltimore
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Jun 9, 2026 · NCT06170970Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Jun 5, 2026 · NCT05849467Pathological Basis of MRI Signal Changes in Multiple Sclerosis
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 120 · All sexes · Updated Jun 5, 2026 · NCT02659956Genes and Environment in Multiple Sclerosis
- National Institute of Neurological Disorders and Stroke, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated May 14, 2026 · NCT01353547Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
- Johns Hopkins University, Baltimore
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated May 6, 2026 · NCT07389590A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
- Evidera INC., Bethesda
- Evidera, Bethesda
RecruitingObservational study
All ages · Women · Updated Nov 20, 2025 · NCT05170126From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.